Canaccord Genuity Analysts Give vTv Therapeutics (VTVT) a $15.00 Price Target

Canaccord Genuity set a $15.00 price target on vTv Therapeutics (NASDAQ:VTVT) in a research note published on Thursday morning. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages also recently commented on VTVT. Stifel Nicolaus reiterated a buy rating and set a $12.00 price objective on shares of vTv Therapeutics in a research report on Friday, November 3rd. Zacks Investment Research downgraded vTv Therapeutics from a buy rating to a hold rating in a research report on Thursday, October 5th. Finally, Citigroup reiterated an add rating on shares of vTv Therapeutics in a research report on Wednesday, November 8th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of $14.10.

Shares of vTv Therapeutics (NASDAQ:VTVT) opened at $4.15 on Thursday. vTv Therapeutics has a 52-week low of $3.57 and a 52-week high of $8.09. The company has a market capitalization of $127.57 and a price-to-earnings ratio of -2.53.

In other vTv Therapeutics news, Director Paul G. Savas bought 15,000 shares of vTv Therapeutics stock in a transaction dated Thursday, December 7th. The stock was bought at an average price of $4.56 per share, for a total transaction of $68,400.00. Following the completion of the acquisition, the director now directly owns 81,781 shares of the company’s stock, valued at $372,921.36. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.80% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently added to or reduced their stakes in VTVT. Ameriprise Financial Inc. lifted its holdings in shares of vTv Therapeutics by 62.7% in the second quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after purchasing an additional 101,850 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of vTv Therapeutics in the third quarter valued at $481,000. Renaissance Technologies LLC lifted its holdings in shares of vTv Therapeutics by 4.8% in the first quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after purchasing an additional 2,900 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of vTv Therapeutics by 2.1% in the second quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after purchasing an additional 1,976 shares in the last quarter. Institutional investors own 10.42% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.com-unik.info/2017/12/24/canaccord-genuity-analysts-give-vtv-therapeutics-vtvt-a-15-00-price-target-2.html.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Analyst Recommendations for vTv Therapeutics (NASDAQ:VTVT)

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit